Changing the radiation and immune-oncology paradigm with the radioenhancer NBTXR3: overcoming resistance to anti-PD-1 blockade from the bench to the clinic

Pour en savoir plus sur nos technologies, nos collaborations, nos essais cliniques et d’autres sujets, contactez-nous.